MRUS has been the subject of several other research reports. Zacks Investment Research raised shares of Merus from a “hold” rating to a “strong-buy” rating and set a $14.00 target price for the company in a research report on Wednesday, October 7th. HC Wainwright reissued a “buy” rating and issued a $23.00 price objective on shares of Merus in a report on Friday, August 7th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $19.00.
MRUS stock opened at $13.00 on Tuesday. The stock’s 50 day moving average is $12.36 and its two-hundred day moving average is $13.64. Merus has a 52-week low of $10.18 and a 52-week high of $20.64. The company has a market capitalization of $377.55 million, a PE ratio of -4.85 and a beta of 0.54.
Merus (NASDAQ:MRUS) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.59) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.59). The business had revenue of $6.67 million during the quarter, compared to the consensus estimate of $6.79 million. Merus had a negative net margin of 243.85% and a negative return on equity of 66.84%. Equities research analysts anticipate that Merus will post -2.19 EPS for the current fiscal year.
In related news, major shareholder Bvf Partners L. P/Il bought 201,906 shares of the stock in a transaction dated Thursday, September 3rd. The stock was bought at an average cost of $11.17 per share, with a total value of $2,255,290.02. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Bvf Partners L. P/Il acquired 189,651 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were bought at an average price of $11.10 per share, with a total value of $2,105,126.10. The disclosure for this purchase can be found here. Insiders have acquired 538,311 shares of company stock worth $6,084,776 over the last three months. 7.40% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sanders Morris Harris LLC purchased a new position in Merus during the 3rd quarter worth approximately $333,000. Two Sigma Advisers LP boosted its position in shares of Merus by 45.0% in the second quarter. Two Sigma Advisers LP now owns 62,500 shares of the biotechnology company’s stock worth $1,006,000 after buying an additional 19,400 shares during the period. PDT Partners LLC purchased a new position in shares of Merus during the second quarter valued at $187,000. Bank of America Corp DE acquired a new position in Merus during the second quarter valued at $32,000. Finally, BVF Inc. IL raised its position in Merus by 43.6% during the second quarter. BVF Inc. IL now owns 5,090,571 shares of the biotechnology company’s stock valued at $81,907,000 after buying an additional 1,545,917 shares during the period. 64.02% of the stock is owned by institutional investors and hedge funds.
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II clinical trial for the treatment of gastric and non-small cell lung cancers.
See Also: Retained Earnings
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.